Cognitive Neuropeptides Research: Science Overview

TL;DR: Cognitive neuropeptides, including Selank, Semax, Dihexa, and Cerebrolysin, are a class of short-chain peptides and peptide-derived preparations studied in preclinical research for their interactions with neurotrophic pathways (BDNF/TrkB), neurotransmitter systems (GABA-A, angiotensin IV/AT4), and synaptic plasticity. The evidence base is predominantly rodent and in vitro, with some early clinical trial data for Cerebrolysin. None of these compounds are FDA approved for human use in the United States. This pillar post maps the biology, the subfamilies, what the evidence shows, and links to individual compound profiles.

Research-Use Disclaimer: This article is for educational and research reference purposes only. The compounds discussed here are research tools, not approved drugs or dietary supplements in the United States. This content does not constitute medical advice, does not recommend or endorse human use of any compound, and does not describe protocols for personal use. All study findings described below refer to published peer-reviewed research, primarily preclinical. For adults 21+ with a research interest only.

What Are Cognitive Neuropeptides? Definition and Research Context

Cognitive neuropeptides are a loosely defined research category encompassing small peptide compounds, typically 5–15 amino acids, studied for their effects on neurotrophic signaling, synaptic plasticity, and behavioral performance in laboratory models. Unlike classical nootropics (e.g., racetams) that modulate receptor activity directly, many neuropeptides in this class appear to interact with endogenous growth factor systems, particularly the brain-derived neurotrophic factor (BDNF) pathway and the brain renin-angiotensin system, as potential mechanistic anchors for their observed preclinical effects.

The research landscape for this compound class is shaped by several important contextual factors that any accurate treatment of the evidence must acknowledge upfront:

• Geographic origin: A significant portion of the foundational research on compounds like Selank and Semax was conducted in Russian-language literature at institutions including the Institute of Molecular Genetics of the Russian Academy of Sciences. While peer-reviewed and indexed on PubMed, this body of research has historically been less replicated by independent Western laboratories, a meaningful limitation for evidence evaluation.
• Preclinical dominance: Most published studies in this class use rodent behavioral models (passive/active avoidance, Morris water maze, object recognition) with molecular endpoints (BDNF protein levels, receptor binding, mRNA expression). Translational validity to human cognition remains incompletely established.
• Evidence tier range: Individual compounds in this cluster span Tier 2 (multiple peer-reviewed rodent studies with consistent findings) to Tier 3 (limited in vitro or single-model data), with Cerebrolysin being the most studied clinically, albeit in specific neurological research contexts, not healthy-subject cognitive enhancement.

For methodology on how evidence tiers are assigned in the Legendary Labz framework, see: How to Read an Evidence Tier.

What Are the Main Subfamilies Within This Compound Class?

The cognitive neuropeptide research cluster can be organized into three functional subfamilies based on mechanism of action and structural origin:

1. Anxiolytic/Immunomodulatory Peptides (Tuftsin-Derived): Selank

Selank (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide analogue of tuftsin, a naturally occurring tetrapeptide fragment of IgG immunoglobulin studied for immunoregulatory properties. Selank was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is registered in Russia as an anxiolytic nasal spray. It is not FDA approved.

In rodent research, Selank has been studied primarily in two behavioral domains: anxiolytic-like activity and memory/learning performance. A 2003 study by Kozlovskii and Danchev in Neuroscience and Behavioral Physiology documented that Selank (300 µg/kg, repeated administration) significantly improved conditioned active avoidance learning in rats with initially poor learning performance, with effects comparable to piracetam, a well-characterized nootropic reference compound, and notable activation apparent from the first training session (PMID 14552529, doi:10.1023/a:1024444321191).

A 2019 study by Kolik et al. in the Bulletin of Experimental Biology and Medicine examined Selank in a chronic ethanol exposure model, finding that Selank administration (0.3 mg/kg, 7 days) prevented ethanol-induced memory and attention disturbances in rats during alcohol withdrawal, and modulated BDNF content in the hippocampus and frontal cortex, suggesting involvement of neurotrophin signaling in Selank’s observed cognitive effects (PMID 31625062, doi:10.1007/s10517-019-04588-9).

The molecular mechanism of Selank’s anxiolytic-like activity was explored in a 2018 study by Vyunova et al. in Protein and Peptide Letters, which used radioligand binding assays to demonstrate that Selank acts as a positive allosteric modulator of GABA-A receptors, a finding mechanistically consistent with anxiolytic-like activity in rodent models and providing a receptor-level hypothesis distinct from benzodiazepines, which act at overlapping but not identical binding sites (PMID 30255741, doi:10.2174/0929866525666180925144642).

For the individual compound profile: What Is Selank? Science and Evidence Explained.

2. ACTH-Derived Nootropic Peptides: Semax

Semax (sequence: Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide analogue of the N-terminal fragment of adrenocorticotropic hormone, ACTH(4-10). Unlike full ACTH, Semax lacks corticosteroid-stimulating activity, having been modified specifically to retain and amplify the fragment’s neurological effects. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and is approved in Russia and Ukraine as a nasal spray for acute ischemic stroke and other neurological indications. It is not FDA approved.

The most extensively characterized mechanistic finding for Semax is its upregulation of BDNF and the TrkB receptor in rodent brain tissue. A 2006 study by Dolotov et al. in Brain Research demonstrated that a single intranasal administration of Semax (50 µg/kg) to rats produced a 1.4-fold increase in hippocampal BDNF protein levels, a 1.6-fold increase in TrkB tyrosine phosphorylation, and a 3-fold increase in BDNF exon III mRNA, changes associated with improved conditioned avoidance performance in the same animals. The authors concluded that Semax affects cognitive brain functions in rodents by modulating the expression and activation of the hippocampal BDNF/TrkB system (PMID 16996037, doi:10.1016/j.brainres.2006.07.108).

A companion 2006 study by the same group, published in the Journal of Neurochemistry, identified specific binding sites for Semax in rat basal forebrain membranes (dissociation constant KD = 2.4 nM), confirmed calcium-dependent binding kinetics, and showed that intranasal Semax at both 50 and 250 µg/kg produced rapid BDNF protein increases in the basal forebrain within 3 hours, but not in the cerebellum, suggesting regional specificity. The authors noted the findings were consistent with a mechanism linking Semax’s cognitive effects to local BDNF upregulation at its binding sites rather than diffuse CNS distribution (PMID 16635254, doi:10.1111/j.1471-4159.2006.03658.x).

An important limitation to state: both Semax BDNF studies originated from the same Russian research group. Independent replication of the BDNF/TrkB findings by separate laboratories would strengthen the mechanistic case significantly. The broader neuroprotective claims circulating online for Semax extend well beyond the replicated evidence base and should be regarded with appropriate skepticism.

For the individual compound profile: What Is Semax? Science and Evidence Explained.

3. Angiotensin-Derived Synaptic Peptides: Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide; also designated PNB-0408) is a small, metabolically stable synthetic analogue of angiotensin IV (AngIV), developed at Washington State University. Angiotensin IV is the N-truncated fragment AngIV[3-8] of the renin-angiotensin system. The brain renin-angiotensin system, distinct from the peripheral cardiovascular system, has been studied for its role in learning and memory through the AT4 receptor subtype (variously proposed to be identical to insulin-regulated aminopeptidase, IRAP, or coincident with the hepatocyte growth factor/c-Met receptor system).

A 2014 review by Wright, Kawas, and Harding in Progress in Neurobiology summarized the development of AngIV analogues including Dihexa, reporting that in rodent models of memory impairment, Dihexa demonstrated the ability to penetrate the blood-brain barrier and augment synaptic connectivity, proposed to occur via formation of new functional synapses through the HGF/c-Met signaling axis. The authors noted Dihexa was approximately 1, 000-fold more potent than its parent compound AngIV in rodent memory models (PMID 25455861, doi:10.1016/j.pneurobio.2014.11.004).

A 2018 systematic review by Ho and Nation in Neuroscience and Biobehavioral Reviews examined 32 studies meeting inclusion criteria for cognitive effects of AngIV and its analogues. Of 9 studies using models of cognitive deficit, 8 found AngIV and its analogues, including Dihexa, improved performance on spatial working memory and passive avoidance tasks. The review noted that effects were most pronounced with intracerebroventricular administration close to the time of learning acquisition, a delivery route not applicable outside highly controlled laboratory settings (PMID 29733881, doi:10.1016/j.neubiorev.2018.05.005).

A 2024 study by Wells et al. in the Journal of Huntington’s Disease tested Dihexa in a rat model of Huntington’s disease-like symptoms (3-NP neurotoxicity) and found it did not protect against motor or cognitive deficits in that model, concluding that further research in alternate models was needed. This null finding is an important corrective to oversimplified summaries of Dihexa’s preclinical record (PMID 38489193, doi:10.3233/JHD-231507).

For the individual compound profile: What Is Dihexa? Science and Evidence Explained.

Cerebrolysin: The Neurotrophic Preparation With the Broadest Clinical Evidence Base

Cerebrolysin is qualitatively different from the synthetic peptides discussed above. It is a standardized preparation of low-molecular-weight neuropeptide fragments and free amino acids derived from porcine brain tissue via controlled enzymatic hydrolysis, manufactured by EVER Neuro Pharma. Its pharmacological properties are attributed to multiple peptide fragments that collectively mimic and modulate endogenous neurotrophic factor activity, rather than a single defined molecular target. Cerebrolysin is approved in several non-US markets (Austria, China, Russia, and others) for neurological indications including post-stroke rehabilitation and dementia. It is not FDA approved.

A 2023 comprehensive review by Rejdak, Sienkiewicz-Jarosz, Bienkowski, and Alvarez in Medicinal Research Reviews, one of the most thorough recent syntheses of the neurotrophic factor literature in the context of neurological disease, examined Cerebrolysin’s effects on five neurotrophic factors: NGF, IGF-1, BDNF, VEGF, and TNF-alpha. The review documented Cerebrolysin’s ability to modulate endogenous NTF expression and concluded that its demonstrated beneficial effects in vitro and in clinical studies for dementia, stroke, and traumatic brain injury are mechanistically consistent with neurotrophic factor theory (PMID 37052231, doi:10.1002/med.21960).

It is important to note that even Cerebrolysin’s clinical evidence is concentrated in specific neurological research contexts, acute stroke rehabilitation, vascular dementia, and traumatic brain injury, not in healthy-subject cognitive enhancement. Researchers studying Cerebrolysin outside these clinical contexts should weigh findings in light of the population-specificity of the supporting evidence.

For the individual compound profile: What Is Cerebrolysin? Science and Evidence Explained.

How Are These Compounds Studied Mechanistically? The BDNF/Neurotrophic Pathway

BDNF (Brain-Derived Neurotrophic Factor) is a member of the neurotrophin family that supports the survival, differentiation, and synaptic plasticity of neurons in the central and peripheral nervous systems. It acts primarily through the TrkB (tropomyosin receptor kinase B) receptor, activating downstream signaling cascades, PI3K/Akt, MAPK/ERK, and PLCγ, that regulate gene expression, long-term potentiation (LTP), and structural synaptic changes associated with learning and memory consolidation.

A 2015 review by Ménard, Gaudreau, and Quirion in the Handbook of Experimental Pharmacology summarized the signaling pathways relevant to cognition-enhancing research, documenting BDNF and its upstream modulators as a “central node” in synaptic plasticity and memory formation, a framework within which the BDNF-modulating effects observed for Semax and Selank in rodent studies acquire mechanistic plausibility (PMID 25977080, doi:10.1007/978-3-319-16522-6_3).

The key mechanistic claims associated with each compound in this cluster, as documented in published preclinical literature, are summarized below:

What Does the Evidence Show? An Honest Evidence Tier Assessment

Researchers approaching this compound class should apply rigorous evidence standards rather than relying on community discussion, anecdotal reports, or marketing material from peptide vendors. The following table summarizes the evidence profile for each compound as documented in indexed peer-reviewed literature as of mid-2026:

A note on strong vs. emerging evidence in this cluster: The strongest evidence within this class belongs to Cerebrolysin, where controlled clinical trial data exists for neurological injury and disease contexts, though that evidence does not extend to healthy-subject cognitive enhancement. Semax and Selank have mechanistically coherent preclinical evidence concentrated in Russian research institutions, with limited independent replication. Dihexa has a plausible mechanistic hypothesis (HGF/c-Met/AT4) and supporting data in some rodent deficit models, but a null finding in at least one 2024 model, and no clinical trial data. For all compounds in this cluster, the absence of large, placebo-controlled human RCTs means human efficacy and safety profiles remain scientifically unestablished. Animal model findings, even internally consistent ones, do not guarantee translational validity.

Regulatory and WADA Status

FDA (United States)

None of the compounds in this cognitive neuropeptide cluster, Selank, Semax, Dihexa, are approved by the U.S. FDA as drugs, biologics, or dietary supplement ingredients. Cerebrolysin is likewise not FDA approved, though it holds regulatory approvals in Austria (EMA-registered), China, Russia, and a number of other markets for specific neurological indications. Researchers in the United States should consult current FDA guidance and relevant institutional requirements before working with any compound in this class.

WADA (World Anti-Doping Agency)

The World Anti-Doping Agency’s Prohibited List places all non-approved pharmacological substances under Section S0: Non-Approved Substances. This category covers any pharmacological substance not currently approved by a governmental regulatory authority for human therapeutic use in any country. Selank, Semax, and Dihexa all fall under S0 for athletes subject to WADA rules. Cerebrolysin, while approved in some jurisdictions, is not approved by the FDA, and its WADA status for athletes in jurisdictions where it lacks approval should be confirmed through current WADA guidance. The S0 prohibition applies both in-competition and out-of-competition.

Frequently Asked Questions: Cognitive Neuropeptides

What are cognitive neuropeptides and how are they studied?

Cognitive neuropeptides are a research category of short-chain peptide compounds studied in preclinical models for their interactions with neurotrophic pathways (particularly BDNF/TrkB), neurotransmitter systems (GABA-A, renin-angiotensin), and synaptic plasticity mechanisms. Research tools include rodent behavioral models, passive/active avoidance, Morris water maze, object recognition, combined with molecular assays measuring BDNF protein, receptor binding, and gene expression. Most of this compound class lacks human randomized controlled trial data; the evidence base is predominantly animal model and in vitro research.

What is Selank and what does the research show?

Selank is a synthetic heptapeptide analogue of the immunopeptide tuftsin, developed at the Institute of Molecular Genetics, Russian Academy of Sciences. Peer-reviewed rodent studies document anxiolytic-like activity in behavioral models and modulation of BDNF levels in the hippocampus and prefrontal cortex (PMID 31625062). A 2018 radioligand study found Selank acts as a positive allosteric modulator of GABA-A receptors at concentrations tested (PMID 30255741). Human clinical data in English-language indexed literature for cognitive endpoints has not been identified. Selank is not FDA approved and falls under WADA Section S0.

What is Semax and how does it relate to BDNF?

Semax is a synthetic analogue of ACTH(4-10) approved in Russia and Ukraine as a nasal spray. Two 2006 studies by Dolotov et al. in Brain Research and Journal of Neurochemistry documented that intranasal Semax administration to rats significantly increased BDNF protein levels and TrkB receptor activation in the hippocampus and basal forebrain, associated with improved avoidance learning. These findings have not been widely replicated by independent groups. Semax is not FDA approved in the United States.

What is the regulatory and WADA status of this compound class?

None of the research-stage cognitive neuropeptides, Selank, Semax, Dihexa, are FDA approved. Cerebrolysin holds approvals in certain non-US markets but is not FDA approved. All unapproved pharmacological substances in this class fall under WADA Section S0 (Non-Approved Substances), prohibiting use in athletes both in-competition and out-of-competition. These are research tools, not approved medicines in the United States.

For educational and research reference purposes only. Not medical advice. Not for human use. These compounds are not approved by the FDA for any human therapeutic use in the United States. This article documents published scientific literature for educational and reference purposes; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound. All citations link to primary sources on PubMed, read them in full. Must be 21+.